|
|
|
0 members (),
2,769
guests, and
24
robots. |
|
Key:
Admin,
Global Mod,
Mod
|
|
S |
M |
T |
W |
T |
F |
S |
|
|
|
|
|
1
|
2
|
3
|
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
|
26
|
27
|
28
|
29
|
30
|
31
|
|
There are no members with birthdays on this day. |
World Earthquake Report for Friday, 2 October 2026
• M 3.7 - 10 km WSW of South Lake Tahoe, CA
• Moderate mag. 4.1 earthquake - Indonesia: Banda Sea on Friday, Oct 2, 2026,...
• M 2.2 - 5 km SW of Volcano, Hawaii
• M 1.9 - 30 km NNE of Chickaloon, Alaska
• M 2.3 - 4 km SW of Volcano, Hawaii
|
#191241
Tue 22 Oct 2013 02:22:PM
|
Joined: Feb 2001
Posts: 678,977
Launch Director
|
|
Launch Director
Joined: Feb 2001
Posts: 678,977 |
Results of a randomized, phase III, trial show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.  Source: Sequential GO, chemotherapy no benefit for older AML patients according trial
David Cottle
UBB Owner & Administrator
|
|
CMS The Best Conveyancing solicitors conveyancing quotes throughout the UK
For any webhosting enquiries please email webmaster@aus-city.com
|
|
Forums60
Topics853,110
Posts887,905
Members2,960
| |
Most Online102,106
Jul 10th, 2026
|
|
|
|
|
|
